Novel strategies for relapsed and refractory acute myeloid leukemia.
about
Treatment of Acute Myeloid Leukemia in Adolescent and Young Adult PatientsHigh dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a siEffects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies.Sequential intensified conditioning followed by prophylactic DLI could reduce relapse of refractory acute leukemia after allo-HSCT.Distribution and clonality of the vα and vβ T-cell receptor repertoire of regulatory T cells in leukemia patients with and without graft versus host disease.BMP4 is involved in the chemoresistance of myeloid leukemia cells through regulating autophagy-apoptosis balance.Clinical significance of Treg cell frequency in acute myeloid leukemia.Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation.CHAG priming regimen containing of cytarabine, aclacinomycin homoharringtonine and G-CSF for relapsed refractory acute myelogenous leukemia: a modified combination chemotherapeutic combination.Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia.
P2860
Q26799609-4BCA4683-E9F5-4690-B3F1-DF3A72A1B3B6Q34500856-EF36A245-D468-43EC-98E8-76C85CC74EBBQ36151239-AC04875B-DAC4-4318-8653-CA464AF45A13Q36173285-15542F37-C18E-4DC2-81A8-9D2973F730D6Q37362718-F0B3598D-AE8F-41BA-A742-DFCD6C038C88Q37617625-D3D1DCC6-7943-4DC9-96A3-17B99AB6B1B4Q39094748-2B89B91F-B0CA-49CE-81E4-1CE2199E7B49Q44231376-17B53C65-4A81-4B9A-8DD3-89F21E4BC7FCQ45351795-7175AB3B-A631-4366-B23B-9282713F2180Q45910107-8540D52F-07BD-40DE-A7EA-D075AB4BFD64Q47598339-A87B22A9-6E6E-484C-9D3B-55084A6CC17A
P2860
Novel strategies for relapsed and refractory acute myeloid leukemia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Novel strategies for relapsed and refractory acute myeloid leukemia.
@en
Novel strategies for relapsed and refractory acute myeloid leukemia.
@nl
type
label
Novel strategies for relapsed and refractory acute myeloid leukemia.
@en
Novel strategies for relapsed and refractory acute myeloid leukemia.
@nl
prefLabel
Novel strategies for relapsed and refractory acute myeloid leukemia.
@en
Novel strategies for relapsed and refractory acute myeloid leukemia.
@nl
P2093
P1476
Novel strategies for relapsed and refractory acute myeloid leukemia.
@en
P2093
Alicia Morgans
Anthony R Mato
Selina M Luger
P304
P356
10.1097/MOH.0B013E3282F463D2
P577
2008-03-01T00:00:00Z